Chronic Total Occlusion of Coronary Artery Clinical Trial
Official title:
A Non-Randomized Clinical Study Evaluating Use of the CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries
Verified date | February 2023 |
Source | Praxis Medical Devices Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluate the safety and effectiveness of the CapBuster System medical device in crossing de novo or restenotic chronic total occlusions in coronary arteries
Status | Not yet recruiting |
Enrollment | 26 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Males > 18 years of age and Female patients of non child-bearing potential 2. Clinical diagnosis of coronary arterial disease requiring revascularization as evidenced by Duplex UltraSound, Digital Subtraction Angiography, CT angiography, or MR angiography 3. Subject requires single- or multi-vessel percutaneous coronary intervention (PCI) of de novo or restenotic target lesion (including in-stent restenotic lesions). 4. Subject's lesion(s) is (are) amenable to stent treatment with currently available CE or FDA-approved stents. 5. Presence of coronary arterial de novo or restenotic chronic total occlusion (100% stenosis), with TIMI 0 flow, confirmed by angiography. Vessel distal to the occlusion(s) must be visualized per collateral or retrograde flow. A maximum of 1 target occlusions can be treated per patient. Target occlusion(s) can be in-stent restenosis 6. Target vessel(s) must be = 2.5 mm and = 3.25 mm in diameter proximal to the target occlusion(s) by visual estimate 7. In the opinion of the investigator, life expectancy of > 1 year 8. Willing and able to sign the informed consent form Exclusion Criteria: 1. Target occlusion is within a bypass graft 2. acute coronary syndrome with ST elevation, 3. cardiogenic shock or out of hospital cardiac arrest 4. Subject has signs or symptoms of systemic infection/sepsis (temperature =38.0o Celsius and WBC =12,000 cells/uL). If subject has localized infection, including cellulitis or osteomyelitis, or infection is adequately treated and controlled, per investigator discretion, patient may be enrolled. 5. Known or suspected myocardial infarction or stroke within previous 30 days 6. Currently participating in another investigational drug or device study 7. Female patients of child-bearing potential. 8. Evidence of STEMI within 72 hours of the intended treatment on infarct related or non-infarct related artery. 9. Cardiogenic shock on presentation or during current hospitalization. 10. Known allergies or contraindication to: contrast materials, antiplatelet therapy, aspirin, clopidogrel (Plavix) and ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent (which cannot be adequately premedicated). 11. Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials). 12. Stroke or transient ischemic attack within the prior 3 months. 13. Any target vessel that has evidence of excessive thrombus (e.g. requires target vessel thrombectomy). 14. Any target vessel that has evidence of excessive tortuousity (greater than 60 degree angle) that makes it unsuitable for proper stent delivery and deployment, 15. Any target lesion that requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement (e.g. but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Praxis Medical Devices Ltd |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CTO crossing of the targeted chronic total occlusion | Successful crossing of the targeted chronic total occlusion, defined as angiography confirmed guidewire placement in the true lumen without utilization of a re-entry device. | 30 day follow-up | |
Primary | CapBuster System related clinically significant events | Freedom from CapBuster System related clinically significant perforation, embolization, or dissection, defined as perforations or embolization that require intervention and flow-limiting (type C, D, E) dissections. | 30 day follow-up | |
Secondary | Study procedure | Study procedure success, defined as successful CTO crossing with the absence of in-hospital/outpatient lab significant events and clinically significant perforation, embolization, or dissection caused by use of the CapBuster System | 30 day follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03475888 -
Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization
|
N/A | |
Not yet recruiting |
NCT04917432 -
Early and Midterm Outcomes of Intravascular Ultrasound (IVUS) Versus Non-IVUS Guidance in Complex Coronary Chronic Total Occlusion (CTO) Revascularization.
|
N/A | |
Recruiting |
NCT04944615 -
To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.
|
N/A | |
Completed |
NCT01861860 -
OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA
|
N/A | |
Recruiting |
NCT05142215 -
A Placebo-controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention for the Relief of Stable Angina
|
N/A | |
Active, not recruiting |
NCT05464147 -
DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions
|
N/A | |
Recruiting |
NCT04145167 -
Observational Registry on Clinical Outcome After Diagnosis of Chronic Total Occlusions
|
||
Not yet recruiting |
NCT04965207 -
EvaLuAtion On the cHaracteristics of the True/False lUmen and Its Prognostic Value for cOronary CTO Patients Just Before Stent Implantation
|
||
Active, not recruiting |
NCT05197361 -
Microvascular Coronary Resistance and Absolute Coronary FLOW in Patients With Percutaneous Intervention of a Chronic Total Occlusion
|
||
Recruiting |
NCT05813704 -
Coronary Crossing System in Patients With Coronary Chronic Total Occlusions
|
N/A | |
Recruiting |
NCT03563417 -
ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO
|
N/A | |
Completed |
NCT05377866 -
Holo CTO Proctoring Study
|
||
Completed |
NCT01978860 -
A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter
|
N/A | |
Withdrawn |
NCT02784418 -
The SHINE-CTO Trial
|
N/A | |
Completed |
NCT03988166 -
Chronic Total Occlusion Percutaneous Coronary Intervention Study
|
N/A | |
Completed |
NCT02477579 -
A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions
|
N/A | |
Completed |
NCT03209843 -
Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure (PERFECTO)
|
N/A | |
Completed |
NCT03947398 -
The BLIMP Balloon in Coronary Interventions
|
N/A | |
Active, not recruiting |
NCT04060615 -
Properties of Myocardial Microcirculation in Patients With Different Pathomorphological Substrates, Before and After Recanalization of Coronary Artery CTO
|
N/A |